Injectable Cytotoxic Drugs Market
Number of pages: 100 | Report Format: PDF | Published date: March 31, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 18.45 billion |
|
Revenue Forecast in 2031 |
US$ 33.08 billion |
|
CAGR |
6.7% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Application, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global injectable cytotoxic drugs market was valued at US$ 18.45 billion in 2022 and is expected to register a revenue CAGR of 6.7% to reach US$ 33.08 billion by 2031.
Injectable Cytotoxic Drugs Market Fundamentals
Cytotoxic medications are essential pharmacological classes for treating common diseases, including oncology disorders. These medications are well-known for their ability to destroy malignant cells through cellular degeneration. For several cancer types, cytotoxic injectable medications are recommended as the initial course of treatment. Most non-patent injectable cytotoxic medications can be found as generics on the international market. The significant dependence on cytotoxic medications for cancer treatment and the rising incidence of the disease are the main factors expected to fuel market revenue expansion during the forecast period. Endobronchial intra-tumoral chemotherapy (EITC) is a form of bronchoscopy interventional treatment that entails inserting a normal needle catheter through a flexible bronchoscope straight into the tumoral tissue to administer one or more conventional cytotoxic medicines. As it allows for a higher concentration of chemotherapy medications to be administered directly to the tumor site while limiting systemic toxicity, this method has demonstrated encouraging results in treating lung cancer.
However, additional research is required to assess its efficacy and safety thoroughly. It is comparable to brachytherapy and photodynamic therapy because of its unique effect. Intra-tumoral distribution of cytotoxic medicines offers a loco-regional neo-adjuvant therapy for radiation or surgery in addition to the benefit of the initial elimination of tumoral burden inside the airway lumen in conjunction with mechanical resection. It is a true form of chemotherapy, and the only way it differs from intravenous chemotherapy is the mode of administration. Intra-tumoral injection approach benefits from higher local tissue concentrations, complete lesion perfusion, reduced systemic adverse effects, and increased local delivery precision of therapeutic ingredients. Treatment of several cancers, including melanoma, breast cancer, and lung cancer, has demonstrated significant outcomes when using the intra-tumoral injection approach. More research is required to compare its effectiveness and safety to conventional intravenous chemotherapy.
[65756]
Injectable Cytotoxic Drugs Market Dynamics
The prevalence rate of all cancer types has increased during the past few decades. Africa, Asia, Central America, and South America account for more than 60% of all new cancer diagnoses worldwide, in addition to being responsible for 70% of all cancer-related deaths. The World Health Organization (WHO) estimates that cancer accounts for 8.3 million annual deaths and that over the next 20 years, there will likely be 70% more new cancer cases reported. Due to the collaborative approach taken by non-traditional key players and the existing traditional businesses to create a more customer-centric experience, the healthcare landscape has undergone tremendous transformation. One of the major market trends is partnerships among key companies and pharmacy distributors, which have increased the productivity of the healthcare supply chain.
As a result of the potentially serious side effects of chemotherapy, some people might prefer alternatives. Chemotherapy kills malignant cells, but despite its effectiveness and potential for lifesaving, it is extremely hazardous. Anemia, exhaustion, hair loss, nausea, and vomiting are among the serious adverse effects. Drugs and therapies, such as injectable cytotoxic drugs, address these adverse effects and enhance the quality of life while undergoing therapy. New target-based cytotoxic drug classes are expected to enhance these patient prognoses dramatically. In preclinical and clinical testing, many new medicines showed cytotoxic effectiveness with fewer side effects. The ability to give combination therapy and increase patient tolerance and overall quality of life is why such selective cytotoxicity towards malignant tissues will continue to be regarded as the gold standard of oncologic therapies.
However, future medicines emphasizing immunotherapy and targeted therapy are far more effective than cytotoxic drugs and have fewer adverse effects. These factors are expected to restrain the market revenue expansion for injectable cytotoxic medications in the upcoming years. The inherent diversity of cancer facilitates the burgeoning discipline of precision and individualized medicine. Numerous pharmaceutical companies are investing in PPM cancer treatments because it has been demonstrated that they offer significant patient advantages which cap the growth of the global injectable cytotoxic drugs market.
Injectable Cytotoxic Drugs Market Ecosystem
The global injectable cytotoxic drugs market is analyzed from four perspectives: drug class, application, distribution channel, and region.
Injectable Cytotoxic Drugs Market by Drug Class
[86556]
Based on the drug classes, the global injectable cytotoxic drugs market is segmented into alkylating drugs, cytotoxic antibodies, antimetabolites, plant alkaloids, and others.
The cytotoxic antibodies segment accounts for the largest revenue share of the global injectable cytotoxic drugs market in 2022. Toxins and other cytotoxic agents can be delivered to tumors using antibodies, greatly reducing systemic toxicity and improving therapeutic effectiveness. A monoclonal antibody (mAb) has the benefit of having superior selectivity for antigens expressed on the surface of cancer cells. Recent biotechnology innovations hastened the development of mAb pharmaceutical applications. In an immunoconjugate, a cytotoxic warhead is joined to a mAb by a stable linker in circulation but effectively cleaves in tumor tissue. Designing potent and effective immunoconjugate success depends on the warhead, mAb, and linker. A single mAb-cytotoxic agent conjugate has received FDA approval, and several additional candidates are undergoing various stages of clinical testing.
Injectable Cytotoxic Drugs Market by Application
Based on the applications, the global injectable cytotoxic drugs market is segmented into oncology, rheumatoid arthritis, multiple sclerosis, and others.
The oncology segment accounts for the largest revenue share in the global injectable cytotoxic drugs market in 2022. The worldwide oncology segment is expanding due to the rising cancer burden caused by rising alcohol and tobacco use. In its GLOBOCAN report, the International Agency for Research on Cancer (IARC) estimates that there were roughly 19.3 million new cancer cases and 10 million cancer-related deaths worldwide in 2020. Therefore, it is anticipated that the rising incidence of cancer would encourage the use of oncology diagnostics and treatments everywhere, thereby fostering the expansion of the global injectable cytotoxic drugs market. Furthermore, it is expected that the market revenue will rise due to increased government and non-profit initiatives to raise awareness about cancer prevention. Finding the right medications to treat the particular type of cancer presents the biggest challenge in chemotherapy planning. Individual patient factors must also be considered to determine whether a cytostatic can be effective. Many times, not just one cytostatic agent but a combination of several agents are used. The chemotherapy used depends on several variables, including the kind and stage of cancer. The types of drugs used, the patient's health and capacity to tolerate the drugs, and other factors like how patients respond to the drugs must all be considered. Combination drugs have a greater chance of killing cancer cells because they can target them at different growth cycle stages.
Injectable Cytotoxic Drugs Market by Distribution Channel
Based on the distribution channel, the global injectable cytotoxic drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounted for the largest revenue share of the global injectable cytotoxic drugs market 2022. Hospital pharmacies have the necessary medications to offer patients complete care due to the prevalence of multi-specialty facilities. Due to various factors, such as the growing number of cancer patients, ongoing clinical developments in the field of oncology therapy, and the expanding accessibility of healthcare reimbursements in many developed countries, this segment currently accounts for a sizeable portion of the market's revenue. Since more people are becoming aware of the many benefits of injectable cytotoxic drugs, including the low cost and the low risk of complications, several patients are turning towards cytotoxic injectable medicines. In addition, several government programs provide low-cost, subsidized medications and other needs in hospital pharmacies, enabling patients to access quality care regardless of their financial situation.
Injectable Cytotoxic Drugs Market by Region
Based on the region, the global injectable cytotoxic drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share of the global injectable cytotoxic drugs market in 2022. This large revenue share is attributed to the increased prevalence of cancer in the main market, like the U.S. The American Cancer Society reports that in the U.S. in 2020, there were over 1.8 million new cancer cases and 606,520 fatalities. Lung, colorectal, breast, and prostate cancer are the four most common types of cancer in North America. Due to a developed healthcare infrastructure and rising healthcare spending, the North American injectable cytotoxic drugs market is anticipated to maintain prominence. Since 1991, the number of cancer deaths in the U.S. has decreased by about 29% due to the increased use of advanced oncology treatments.
The market revenue growth in Europe is attributed to several factors, including high healthcare spending on cancer and rheumatoid arthritis, favorable reimbursement policies, and active government initiatives to make chemotherapy drugs more widely available. The European Journal of Cancer reported that in 2018, the continent nations spent about US$ 243.6 billion on cancer treatment. Such rising expenses will fuel market revenue growth in the area.
Asia Pacific is expected to experience substantial revenue growth during the forecast period. A growing patient base and rising healthcare spending in the area support the market revenue growth in Asia Pacific. In addition, the rising purchasing power of the populace in China and India, two emerging economies, presents a significant revenue growth opportunity for the market.
Competitive Landscape of Injectable Cytotoxic Drugs Market
Notable market participants in the injectable cytotoxic drugs market include:
Strategic Development in Injectable Cytotoxic Drugs Market
Cytotoxic drugs are important for treating common diseases such as oncology disorders. These drugs are known for their cellular degeneration properties, which aid in eliminating cancerous cells.
New treatment strategies and increased disease prevalence are the key trends to fuel the revenue growth of the global injectable cytotoxic drugs market.
High cost and lack of awareness about injectable cytotoxic drugs are the factors restricting the revenue growth of the global market.
The global injectable cytotoxic drugs market is expected to grow at a revenue CAGR of 6.7% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain